_2020091018165303jzv.jpg "Decoding The World Of ETF")
Traders cheered Aurobindo's in-line performance by sending the stock nearly 4 percent higher. But they punished Sun Pharma for missing Street estimates across the board by sending the stock down over 6 percent. CNBC-TV18's Ekta Batra and Archana Shukla crunch the numbers.
Two pharma companies, but different stories. That's the picture Sun Pharma and Aurobindo Pharma's quarterly numbers have painted.
And the reaction from the Street has been fitting.
Traders cheered Aurobindo's in-line performance by sending the stock nearly 4 percent higher. But they punished Sun Pharma for missing Street estimates across the board by sending the stock down over 6 percent.
CNBC-TV18's Ekta Batra and Archana Shukla crunch the numbers.
Watch the video for more
First Published on May 31, 2016 09:54 pm